Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 6c, beats revenue

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.53), $0.06 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $40 thousand versus the consensus estimate of $13.47 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Kroger meets earnings expectations, revenue tops estimates